- Home
- FVRR vs VCRE Comparison
FVRR vs VCRE Comparison
Compare FVRR & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FVRR | VCRE |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | Sweden |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 332.9M |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FVRR | VCRE |
|---|---|---|
| Price | $9.37 | $11.50 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.43 | N/A |
| AVG Volume (30 Days) | ★ 956.8K | 4.9K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $10.50 |
| 52 Week High | $28.00 | $13.00 |
Technical Indicators
Market Signals| Indicator | FVRR | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 41.46 |
| Support Level | $8.68 | $10.74 |
| Resistance Level | $11.50 | $11.59 |
| Average True Range (ATR) | 0.33 | 0.64 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 65.67 | 38.80 |
Price Performance
Historical ComparisonAbout FVRR Fiverr International Ltd. no par value
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.